Ghanaian heads International Society of Pharmacovigilance

Dr Alex Dodoo, a 45-year –old Ghanaian Pharmacist, has been elected as President of the International Society of Pharmacovigilance (ISoP) for a three-year term.

Dr Dodoo, who is the President of the Global Drug Safety Organisation and the Pharmaceutical Society of Ghana, will end his term as head of the ISoP at an annual conference in Reims, France in 2012.

A press release from the UK said Dr Dodoo, who takes over from Professor Nicholas Moore of the University of Bordeaux in France becomes the first African and a non- European to be elected into the high and important position in global drug safety.

Dr Dodoo a pharmacist and clinical pharmacologist graduated from the Kwame Nkrumah University of Science and Technology, and King’s College London, UK.

He also undertook a year of research at the University of Alberta, Edmonton, Canada.

Dr Dodoo is currently the Head of the Centre for Tropical Clinical Pharmacology and Therapeutics at the University of Ghana Medical School and leads the Global Outreach team for the World Health Organisation (WHO) Programme for International Drug Monitoring in Uppsala, Sweden.

He is a member of several global committees on drug safety, including the WHO Advisory Committee on the Safety of Medicinal Products, the WHO Expert Panel on Drug Evaluation and a member-at-large of the WHO Global Advisory Committee on Vaccine Safety.

Dr Dodoo is also a member of the Royal Pharmaceutical Society of Great Britain and a Fellow of the West African Postgraduate College of Pharmacy Practice.

He is the President of the Pharmacy Information Section of the International Pharmaceutical Federation, based in The Hague.

The ISoP is an international non-profit scientific organisation, which aims at fostering Pharmacovigilance scientifically and educationally, and enhances all aspects of the safe and proper use of medicines, in all countries.

Its membership is drawn from industry, academia and national drug regulatory agencies.

Source: GNA

Ghanain heads International Society of Pharmacovigilance
Dr Alex Dodoo, a 45-year –old Ghanaian Pharmacist, has been elected as President of the International Society of Pharmacovigilance (ISoP) for a three-year term.
Dr Dodoo, who is the President of the Global Drug Safety Organisation and the Pharmaceutical Society of Ghana, will end his term as head of the ISoP at an annual conference in Reims, France in 2012.
A press release from the UK said Dr Dodoo, who takes over from Professor Nicholas Moore of the University of Bordeaux in France becomes the first African and a non- European to be elected into the high and important position in global drug safety.
Dr Dodoo a pharmacist and clinical pharmacologist graduated from the Kwame Nkrumah University of Science and Technology, and King’s College London, UK.
He also undertook a year of research at the University of Alberta, Edmonton, Canada.
Dr Dodoo is currently the Head of the Centre for Tropical Clinical Pharmacology and Therapeutics at the University of Ghana Medical School and leads the Global Outreach team for the World Health Organisation (WHO) Programme for International Drug Monitoring in Uppsala, Sweden.
He is a member of several global committees on drug safety, including the WHO Advisory Committee on the Safety of Medicinal Products, the WHO Expert Panel on Drug Evaluation and a member-at-large of the WHO Global Advisory Committee on Vaccine Safety.
Dr Dodoo is also a member of the Royal Pharmaceutical Society of Great Britain and a Fellow of the West African Postgraduate College of Pharmacy Practice.
He is the President of the Pharmacy Information Section of the International Pharmaceutical Federation, based in The Hague.
The ISoP is an international non-profit scientific organisation, which aims at fostering Pharmacovigilance scientifically and educationally, and enhances all aspects of the safe and proper use of medicines, in all countries.
Its membership is drawn from industry, academia and national drug regulatory agencies.
Source: GNA
Leave A Reply

Your email address will not be published.

Shares